SOAR AI, Inc. filed a definitive proxy statement on November 4, 2026, soliciting stockholder votes on five proposals at its 2026 Annual Meeting to be held virtually on December 9, 2026, at 9:00 a.m. Eastern Time.
Marchex, Inc. filed its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission for the fiscal year ended December 31, 2025, disclosing its business operations, financial results, and corporate structure as a smaller reporting company listed on NASDAQ:MCHX.
Marchex, Inc. filed a Definitive Proxy Statement (DEF 14A) on November 4, 2026, inviting stockholders to its 2026 Annual Meeting of Stockholders scheduled for December 16, 2026, at 11:00 AM Pacific Time in Seattle, Washington.
USBC, Inc. filed a Transition Report on Form 10-K with the SEC covering the three-month period from October 1, 2025 through December 31, 2025, reflecting the company's change of its fiscal year end from September 30 to December 31.
Microsoft Corporation filed a current report on November 4, 2026, disclosing that it entered into an Underwriting Agreement on October 29, 2026, for the issuance and sale of ten tranches of senior unsecured notes totaling $25,000,000,000 in aggregate principal amount, listed on NASDAQ:MSFT.
Allegiant Travel Company filed a Form 8-K on November 4, 2026, furnishing a press release and earnings call slides covering its results of operations for the quarter ended September 30, 2026.
Braemar Hotels & Resorts Inc. filed soliciting material under Rule 14a-12 on November 4, 2026, reporting its third-quarter financial results for the period ended September 30, 2026, disclosing a net loss of $240.9 million attributable to common stockholders alongside comparable RevPAR growth of 14.4%.
Fox Corporation filed a Form 8-K on November 4, 2026, disclosing the voting results from its Annual Meeting of Stockholders held that same day, covering director elections, auditor ratification, executive compensation, and a stockholder governance proposal.
Moleculin Biotech, Inc. filed a Form 8-K on November 4, 2026, disclosing that an abstract featuring data from its lead drug candidate, Annamycin, has been accepted for presentation at the 2026 American Society of Hematology Annual Meeting.
C. H. Robinson Worldwide, Inc. filed a Form 8-K on November 4, 2026, disclosing amendments to its revolving credit agreement and note purchase agreement, both executed on November 2, 2026, in connection with the company's planned acquisition of RXO, Inc.